Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

In this clinical trial, the Sponsor plans to investigate whether patients with HR+/HER2- eBC identified during routine clinical assessments and treatments as having intermediate to high-risk (based on Oncotype DX® or similar tests and on response assessment to 2-6 weeks of preoperative ET) achieve a survival benefit from an initial 5-years use of elacestrant (with or without a CDK 4/6 inhibitor) followed by SoC ET for further 0-2.5 years in comparison to at least 5 up to 7.5 years SoC ET therapy (+/- CDK4/6 inhibitor). Based on several studies in the metastatic setting, it is reasonable to as

Trial Details

NCT ID
NCT07242352
Phase
PHASE3
Sponsor
Women's Cancer Study Group GmbH
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Elacestrant
  • Standard-of-care endocrine treatment
Locations (sample)
  • Mannheim, Baden-Wurttemberg, Germany|49.4891,8.46694
  • Tübingen, Baden-Wurttemberg, Germany|48.52266,9.05222
  • Esslingen am Neckar, Baden-Wüttemberg, Germany|48.73961,9.30473
  • Freiburg im Breisgau, Baden-Wüttemberg, Germany|47.9959,7.85222
  • Amberg, Bavaria, Germany|49.44287,11.86267

Key Eligibility Criteria

  • All patients, independent from gender
  • Patient must be ≥18 years at diagnosis
  • The patient must be capable of giving informed consent and be willing and able to comply with the requirements and restrictions in this protocol an…
  • Sign informed consent prior to any study-specific procedures.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →